Factors Associated with Cervical Cancer Screening Amongst Women of Reproductive Age from Yucatan, Mexico

  • Published : 2012.09.30


This study aimed to analyse the participation of women of reproductive age in a cancer screening program, and survey reasons for non-screening in a region from Mexico with high cervical cancer mortality. A total of 281 obstetric patients from a previous HPV study in a social security hospital during 2008-2009 were included. Reasons for not participating in the screening were directly asked. HPV positive patients were invited to participate in an informative workshop, and they filled in a knowledge questionnaire. The women ranged in age from 14-47 years; 123 (43.8%) had never participated in screening, of which 97 (78.9%) had their first sexual intercourse 2 to 10 years ago, resulting in 25% HPV positive. Screening history was strongly associated with 2 or more gestations (OR=10.07, p=0.00) and older age (OR=6.69 p=0.00). When 197 women were contacted and interviewed, reasons referred for non-screening were ignorance, lack of interest or time, recent sexual onset, shame and fear. More than 50% of the workshop participants showed knowledge of HPV, while 38.9% and 25% knew about Pap smear and cervical cancer. A high percentage of women of reproductive age have never had a Pap smear. Promoting the screening program in medical facilities seems to be important in this population. New approaches to inform vulnerable individuals on the benefits of screening need to be implemented, especially for young women.


  1. Aguilar-Perez JA, Leyva-Lopez AG, Angulo-Najera D, et al (2003). Tamizaje en cancer cervical: conocimiento de la utilidad y uso de citologia cervical en Mexico. Rev Saúde Pública, 37, 100-6.
  2. Austin LTT, Ahmad F, Mc Nally MJ, et al (2002). Breast and cervical cancer screening in Hispanic Women a Literature review using the health belief model. Women's Health Iss, 12, 122-8.
  3. Byrd T, Peterson SK, Chavez R, et al (2004). Cervical cancer screening beliefs among young hispanic women. Prev Med, 38, 192-7.
  4. Carrillo A, Mohar A, Meneses A, et al (2004). Utilidad en la combinacion de oligonucleotidos universales para la deteccion del virus del papiloma humano en cancer cervicouterino y lesiones premalignas. Salud Publica Mex, 46, 7-15.
  5. Flores K, Bencomo C (2009). Preventing cervical cancer in the Latin population. J Womens Hlth, 18, 1935-43.
  6. Gonzalez-Losa MR, Canto-Perez JL, Puerto-Solis M (2006b). Cervical cancer screening: knowledge among student workers in a rural area of Mexico. Qual Prim Care, 14, 205-9.
  7. Gonzalez-Losa MR, Hidalgo-Martinez AC, Manzano-Cabrera L, et al (2006a). Absence of DNA human papillomavirus type 16 in mexican women with normal pap smear. Int J Virol, 2, 59-62.
  8. Hernandez-Avila M, Lazcano-Ponce EC, Alonso de Ruiz P, et al (1998). Evaluation of the cervical cancer screening program in Mexico: a population-based case-control study. Int J Epidemiol, 27, 370-6.
  9. Huamani C, Hurtado-Ortega A, Guardia-Ricra M, et al (2008). Conocimientos y actitudes sobre la toma de Papanicolaou en mujeres de Lima, Peru. Rev Peru Med Exp Salud Publica, 25, 44-50.
  10. Kyrgiou M, Koliopoulos G, Martin-Hirsch PL, et al (2006). Obstetric outcome after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet, 367, 489-98.
  11. Lazcano PE, Najera AP, Buiatti E, et al (1997). The cervical cancer screening program in Mexico: problems with access and coverage. Cancer Causes Control, 8, 698-704.
  12. Lazcano Ponce E, Moss S, Cruz VA, et al (1999b). Factores que determinan la participacion en el tamizaje de cancer cervical en el estado de morelos. Salud Publica Mex, 41, 278-85.
  13. Lazcano PE, Moss S, Alonso de Ruiz P, et al (1999a). Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res, 30, 240-50.
  14. Lazcano-Ponce E, Palacio-Mejia LS, Allen-Leigh B, et al (2008). Decreasing cervical cancer mortality in Mexico: effect of papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. Cancer Epidemiol Biomarkers Prev, 17, 2808-17.
  15. Leyva M, Byrd T, Tarwater P (2006). Attitudes towards cervical cancer screening: a study of beliefs among women in Mexico. California J Hlth Promotion, 4, 13-24.
  16. Manos M, Ting Y, Wright D, et al (1989). The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer cells, 7, 209-14.
  17. Margolis KL, Lurie N, McGovern PG, et al (1998). Increasing breast and cervical cancer screening in low-income women. J Gen Intern Med, 13, 515-21.
  18. Nene B, Jayant K, Arrossi S, et al (2007). Determinants of women's participation in cervical cancer trial, Maharashtra, India. Bull World Hlth Org, 85, 264-72.
  19. Noller KL (2005). Cervical cytology screening and evaluation. Obstet Gynecol, 106, 391-7.
  20. Rieck GC, Tristram A, Hauke A, et al (2006). Cervical screening in 20-24-year olds. J Med Screen, 13, 64-71.
  21. Rodriguez ER, Cerda RM, Solis NP, et al (2003). Identificacion y tipificacion del virus del papiloma humano en mujeres usuarias del programa "Deteccion Oportuna de Cancer" en Durango, Mexico. Ginecol Obstet Mex, 71, 471-5.
  22. Sasieni P, Castanon A, Cuzick J (2009). Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ, 339, 2968.
  23. Secretaria de Salud, Mexico. Norma Oficial mexicana NOM- 014-SSA2-1994 para la prevencion, deteccion, diagnostico, tratamiento, control y vigilancia epidemiologica del Cancer Cervico Uterino. Diario Oficial de la Federacion, March 6th 1998.
  24. Secretaria de Salud, Mexico. Direccion General Adjunta de Epidemiologia. Anuarios de morbilidad. Estadisticas 2009. (cited july 2011). Available from
  25. Secretaria de Salud, Mexico. Estadisticas de mortalidad 2008. Mexico. (cited on 8 july 2011) Available from:
  26. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  27. Wall KM, Rocha GM, Salinas-Martinez AM, et al (2010). Modifiable barriers to cervical cancer screening adherence among working women in Mexico. J Womens Hlth, 19, 1263-70.
  28. Woodman CI, Collins S, Winter H, et al (2001). Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, 357, 1831-6.
  29. World Health Organization (WHO). Causes of Death: 2008 Summary Tables. Health statistics and informatics Department. Worl Health Organization, Geneva, Switzerland; 2011.
  30. Yang L, Fujimoto J, Qiu D, et al (2009). Trends in cancer mortality in Japanese adolescents and young adults aged 15-29 years, 1970-2006. Ann Oncol, 20, 758-66.
  31. Yang B, Morrell S, Zuo Y, et al (2008). A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. Cancer Causes Control, 19, 569-76.

Cited by

  1. Cervical Cancer Trends in Mexico: Incidence, Mortality and Research Output vol.15, pp.20, 2014,
  2. Social and Cultural Barriers to Women’s Participation in Pap Smear Screening Programs in Low- and Middle-Income Latin American and Caribbean Countries: An Integrative Review vol.29, pp.6, 2018,